CN106822028A - A kind of Tadalafei soft capsule preparation and its preparation technology - Google Patents
A kind of Tadalafei soft capsule preparation and its preparation technology Download PDFInfo
- Publication number
- CN106822028A CN106822028A CN201710079754.4A CN201710079754A CN106822028A CN 106822028 A CN106822028 A CN 106822028A CN 201710079754 A CN201710079754 A CN 201710079754A CN 106822028 A CN106822028 A CN 106822028A
- Authority
- CN
- China
- Prior art keywords
- soft capsule
- tadalafei
- preparation
- content
- gelatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of Tadalafei soft capsule preparation, including soft capsule and content, content prescription is：Tadalafei raw material 0.1g ~ 0.5g；Labraso 200g ~ 250g；Unigly GO 102S 30g ~ 60g；Median chain triglyceride oil 50g ~ 100g；2,6 BHT 0.02g ~ 0.05g.Tadalafei soft capsule of the invention, can significantly improve the accumulation dissolution rate of dissolution 5 minutes, improve dissolution efficiency of the main ingredient in the preceding time period；With good stability, product appearance quality is good.
Description
Technical field
The present invention relates to technical field of medicine, and in particular to a kind of Tadalafei soft capsule preparation and its preparation work
Skill.
Background technology
Tadalafei（tadalafil）Also known as Xi Aili（Cialis）, there is more preferable selectivity to PDE5.In October, 2003
Listed in the U.S. first by Eli Lilly companies of the U.S., on October 6th, 2011, FDA (Food and Drug Adminstration)（FDA）Ratify him
Da Lafei (tadalafil, trade name Cialis) is used to treat benign prostatic hyperplasis (benign prostatic
Hyperplasia, BPH), the disease shows as prostatitis hylperadenosis.Tadalafei was approved for treating ED in 2003（Suddenly
Play dysfunction）, import, trade name have also been approved in China：Xi Aili.Erectile dysfunction is typically to indicate that stem can not reach
To, maintain to be enough to complete a kind of disease of rigidity required for a sexual intercourse, be commonly called as ED.The ED patient included in worldwide is about
There are 1.5 hundred million people, only the U.S. is more than 30,000,000.Cut-off 2011, global ED markets only have three medicines for treatment：Silaenafil,
Tadalafei and Vardenafil.Tadalafei is to work in these three ED medicines most fast, and duration of efficacy is most long, and it is unique not
The medicine influenceed by high fat diet and Ethanol intake.Silaenafil (being commonly called as " vigour ") is global first phosphodiesterase -5
Inhibitor, its business success not only increases understanding of the society to this disease, and causes that more male patients are happy to connect
By and actively seek treatment.But investigation finds, also only 10% erectile dysfunction male uses silaenafil now.It is huge
Do not receive treatment patient population indicate that ED pharmaceutical markets still suffer from huge commercial opportunity.Tadalafei (trade name
" Cialis " " Xi Aili ") and Vardenafil all be second generation phosphodiesterase 5 inhibitor, their listing again be such medicine
New vitality is injected in thing market, and for erectile dysfunction male provides, more side effects are smaller, clinical efficacy is clearly new
Selection.Tadalafei pharmacological action feature：Tadalafei it is oral through gastrointestinal absorption after, can be worked in 30 minutes, and curative effect
Continue 36 hours, be to work in current only three kinds of ED medicines most fast, duration of efficacy is most long, and unique not by fat high drink
Food and the medicine of Ethanol intake influence.Silaenafil and Vardenafil need to shift to an earlier date 3 hours and take, and duration of efficacy is no more than 1
Hour, alcohol and high fat diet influence the performance of drug effect.By these obvious drug effect advantages, Tadalafei is listing first year
Sales volume is that, more than 200,000,000 dollars, global marketing volume has broken through 18.7 hundred million dollars within 2011." cookle " medicine is easily ranked among
Ranks.U.S.'s listing has 4 kinds of specifications, and every is respectively 2.5 mg, 5 mg, 10 mg and 20 mg containing Tadalafei.
The content of the invention
It is an object of the invention to provide a kind of Tadalafei soft capsule preparation.
It is, up to above-mentioned purpose, a kind of Tadalafei soft capsule preparation to be provided in one embodiment of the present of invention, including it is soft
Capsule and content, content prescription is：
0.1~0.5g of Tadalafei raw material；
Labraso 200g~250g；
Unigly GO 102S 30g~60g；
Median chain triglyceride oil 50g~100g；
DBPC 2,6 ditertiary butyl p cresol 0.02g~0.05g.
In a preferred scheme of the invention, content prescription is：
Tadalafei raw material 0.1g；
Labraso 220g~240g；
Unigly GO 102S 40g~50g；
Median chain triglyceride oil 60g~90g；
DBPC 2,6 ditertiary butyl p cresol 0.03g~0.04g.
In a preferred scheme of the invention, content prescription is：
Tadalafei raw material 0.2g；
Labraso 220g；
Unigly GO 102S 45g；
Median chain triglyceride oil 75g；
DBPC 2,6 ditertiary butyl p cresol 0.035g.
In a preferred scheme of the invention, content prescription is：
Tadalafei raw material 0.5g；
Labraso 235g；
Unigly GO 102S 48g；
Median chain triglyceride oil 78g；
DBPC 2,6 ditertiary butyl p cresol 0.04g.
In a preferred scheme of the invention, the prescription of soft capsule is：
Gelatin 140mg~180mg；
Glycerine 70mg~100mg；
Yellow ferric oxide 0.1mg~0.4mg；
Titanium dioxide 1mg~3mg.
In a preferred scheme of the invention, the prescription of soft capsule is：
Gelatin 160mg；
Glycerine 80mg；
Yellow ferric oxide 0.29mg；
Titanium dioxide 2mg.
In a preferred scheme of the invention, the prescription of soft capsule is：
Gelatin 150mg；
Glycerine 90mg；
Yellow ferric oxide 0.35mg；
Titanium dioxide 2.5mg.
Another object of the present invention is to improve a kind of technique for preparing Tadalafei soft capsule preparation, including following step
Suddenly：
(1) content is prepared：Take Labraso, Unigly GO 102S and the acid of medium chain triglyceride three of recipe quantity
Ester is stirred, and the Tadalafei bulk drug and BHT of recipe quantity are added after intensification, continues to stir
After be down to room temperature, obtain content；
(2) soft capsule is prepared：It is uniformly mixed in glycerine addition water the being placed in glue tank for taking recipe quantity, is subsequently adding sieving
Titanium dioxide and yellow ferric oxide are well mixed, are subsequently adding gelatin and are heated to 60 DEG C~80 DEG C；Continue to stir to gelatin
It is completely dissolved；Vacuum is opened after Gelatin makes glue deaerate, and degassing is lowered the temperature after finishing；
(3) pill：Inside Contents Fill to soft capsule, will shape, dry using soft capsule, obtain pastille soft capsule.
In a preferred scheme of the invention, Labraso, Unigly GO 102S and medium chain triglyceride
Three acid esters are stirred, and Tadalafei bulk drug and BHT are added after being warming up to 40 DEG C.
In a preferred scheme of the invention, the capsule severe edema due to hypofunction of the spleen of pastille soft capsule is divided into 8%~12%.
Unigly GO 102S of the invention is bought in the product Unigly GO 102S of the good method lion of France.
In sum, the present invention has advantages below：
Tadalafei soft capsule of the invention, can significantly improve the accumulation dissolution rate of dissolution 5 minutes, improve main ingredient in the preceding time
The dissolution efficiency of section；With good stability, product appearance quality is good.Secondly the present invention is selected by the optimization to component
Select, reduce harmful effect of the propane diols to main ingredient migration, stability, dissolution rate and bioavailability.
Specific embodiment
Embodiment 1
Tadalafei soft capsule preparation content prescription：
Tadalafei raw material 0.1g；Labraso 200g；
Unigly GO 102S 45g；Median chain triglyceride oil 75g；
DBPC 2,6 ditertiary butyl p cresol 0.035g.
Soft capsule prescription：
Gelatin 160mg；Glycerine 80mg；
Yellow ferric oxide 0.29mg；Titanium dioxide 2mg.
Preparation method：
(1) content is prepared：Take Labraso, Unigly GO 102S and the acid of medium chain triglyceride three of recipe quantity
Ester stirs, and is warmed up to after 40 DEG C and adds the Tadalafei bulk drug and BHT of recipe quantity, continues to stir
1h is mixed to room temperature is down to after uniform, content is obtained；
(2) soft capsule is prepared：It is uniformly mixed in glycerine addition water the being placed in glue tank for taking recipe quantity, was subsequently adding 80 mesh
The titanium dioxide and yellow ferric oxide of sieve are well mixed, and are subsequently adding gelatin and are heated to 70 DEG C；Continue to stir 1h to gelatin
Stop stirring after being completely dissolved；Vacuum holding vacuum bag -0.09Mpa is opened after Gelatin makes glue degassing 30min, has deaerated
Lower the temperature 60 DEG C after finishing, it is standby after standing 24h；
(3) pill：Encapsulating machine is heated after being debugged to sprinkler body；Adjustment revolving die pressure, is advisable with just extruding capsule and pill,
Pressure is avoided to cross conference mold damage.Loading amount regulation is carried out, sampling detection extrudes crack quality, outward appearance, the content weight of capsule and pill,
Adjust in time, untill meeting the requirements；Roller is opened, the capsule and pill sizing that will be suppressed；The capsule and pill of compacting is determined in roller
Taken out after type, be placed in 30 DEG C, dried in the environment of below RH50%, and the sampling detection capsule severe edema due to hypofunction of the spleen point at any time, when the capsule severe edema due to hypofunction of the spleen point exists
When 8%~12%, stop drying.
Embodiment 2
Tadalafei soft capsule preparation content prescription：
Tadalafei raw material 0.2g；Labraso 205g；
Unigly GO 102S 50g；Median chain triglyceride oil 72g；
DBPC 2,6 ditertiary butyl p cresol 0.038g.
Soft capsule prescription：
Gelatin 160mg；Glycerine 80mg；
Yellow ferric oxide 0.25mg；Titanium dioxide 2.2mg.
Preparation method：
(1) content is prepared：Take Labraso, Unigly GO 102S and the acid of medium chain triglyceride three of recipe quantity
Ester stirs, and is warmed up to after 40 DEG C and adds the Tadalafei bulk drug and BHT of recipe quantity, continues to stir
1h is mixed to room temperature is down to after uniform, content is obtained；
(2) soft capsule is prepared：It is uniformly mixed in glycerine addition water the being placed in glue tank for taking recipe quantity, was subsequently adding 80 mesh
The titanium dioxide and yellow ferric oxide of sieve are well mixed, and are subsequently adding gelatin and are heated to 70 DEG C；Continue to stir 1h to gelatin
Stop stirring after being completely dissolved；Vacuum holding vacuum bag -0.09Mpa is opened after Gelatin makes glue degassing 30min, has deaerated
Lower the temperature 60 DEG C after finishing, it is standby after standing 24h；
(3) pill：Encapsulating machine is heated after being debugged to sprinkler body；Adjustment revolving die pressure, is advisable with just extruding capsule and pill,
Pressure is avoided to cross conference mold damage.Loading amount regulation is carried out, sampling detection extrudes crack quality, outward appearance, the content weight of capsule and pill,
Adjust in time, untill meeting the requirements；Roller is opened, the capsule and pill sizing that will be suppressed；The capsule and pill of compacting is determined in roller
Taken out after type, be placed in 30 DEG C, dried in the environment of below RH50%, and the sampling detection capsule severe edema due to hypofunction of the spleen point at any time, when the capsule severe edema due to hypofunction of the spleen point exists
When 8%~12%, stop drying.
Embodiment 3
Tadalafei soft capsule preparation content prescription：
Tadalafei raw material 0.3g；Labraso 210g；
Unigly GO 102S 45g；Median chain triglyceride oil 75g；
Soft capsule prescription：
Gelatin 161mg；Glycerine 85mg；
Yellow ferric oxide 0.27mg；Titanium dioxide 2mg.
Preparation method：
(1) content is prepared：Take Labraso, Unigly GO 102S and the acid of medium chain triglyceride three of recipe quantity
Ester stirs, and is warmed up to after 40 DEG C and adds the Tadalafei bulk drug of recipe quantity to continue to stir 1h to being down to room temperature after uniform,
Obtain content；
(2) soft capsule is prepared：It is uniformly mixed in glycerine addition water the being placed in glue tank for taking recipe quantity, was subsequently adding 80 mesh
The titanium dioxide and yellow ferric oxide of sieve are well mixed, and are subsequently adding gelatin and are heated to 70 DEG C；Continue to stir 1h to gelatin
Stop stirring after being completely dissolved；Vacuum holding vacuum bag -0.09Mpa is opened after Gelatin makes glue degassing 30min, has deaerated
Lower the temperature 60 DEG C after finishing, it is standby after standing 24h；
(3) pill：Encapsulating machine is heated after being debugged to sprinkler body, and control temperature is at 35 DEG C；Adjustment revolving die pressure, with firm
Extrude capsule and pill well to be advisable, it is to avoid pressure crosses conference mold damage.Loading amount regulation is carried out, sampling detection extrudes the crack matter of capsule and pill
Amount, outward appearance, content weight, adjust, untill meeting the requirements in time；Roller is opened, the capsule and pill sizing that will be suppressed；Will pressure
The capsule and pill of system takes out after roller sizing, is placed in 30 DEG C, is dried in the environment of below RH50%, and the capsule severe edema due to hypofunction of the spleen of sampling detection at any time
Point, when the capsule severe edema due to hypofunction of the spleen point is 8%~12%, stop drying.
Embodiment 4
Tadalafei soft capsule preparation content prescription：
Tadalafei raw material 0.5g；Labraso 210g；
Unigly GO 102S 40g；Median chain triglyceride oil 70g；
Butylated hydroxy anisole BHA0.035g.
Soft capsule prescription：
Gelatin 160mg；Glycerine 85mg；
Yellow ferric oxide 0.28mg；Titanium dioxide 2mg.
Preparation method：
(1) content is prepared：Take Labraso, Unigly GO 102S and the acid of medium chain triglyceride three of recipe quantity
Ester stirs, and is warmed up to after 40 DEG C and adds the Tadalafei bulk drug and butylated hydroxy anisole BHA of recipe quantity to continue to stir
1h obtains content to room temperature is down to after uniform；
(2) soft capsule is prepared：It is uniformly mixed in glycerine addition water the being placed in glue tank for taking recipe quantity, was subsequently adding 80 mesh
The titanium dioxide and yellow ferric oxide of sieve are well mixed, and are subsequently adding gelatin and are heated to 70 DEG C；Continue to stir 1h to gelatin
Stop stirring after being completely dissolved；Vacuum holding vacuum bag -0.09Mpa is opened after Gelatin makes glue degassing 30min, has deaerated
Lower the temperature 60 DEG C after finishing, it is standby after standing 24h；
(3) pill：Encapsulating machine is heated after being debugged to sprinkler body；Adjustment revolving die pressure, is advisable with just extruding capsule and pill,
Pressure is avoided to cross conference mold damage.Loading amount regulation is carried out, sampling detection extrudes crack quality, outward appearance, the content weight of capsule and pill,
Adjust in time, untill meeting the requirements；Roller is opened, the capsule and pill sizing that will be suppressed；The capsule and pill of compacting is determined in roller
Taken out after type, be placed in 30 DEG C, dried in the environment of below RH50%, and the sampling detection capsule severe edema due to hypofunction of the spleen point at any time, when the capsule severe edema due to hypofunction of the spleen point exists
When 8%~12%, stop drying.
Embodiment 5
Tadalafei soft capsule preparation content prescription：
Tadalafei raw material 0.4g；Labraso 220g；
Unigly GO 102S 46g；Median chain triglyceride oil 75g；
Sodium pyrosulfite 0.036g.
Soft capsule prescription：
Gelatin 160mg；Glycerine 85mg；
Yellow ferric oxide 0.28mg；Titanium dioxide 2mg.
Preparation method：
(1) content is prepared：Take Labraso, Unigly GO 102S and the acid of medium chain triglyceride three of recipe quantity
Ester stirs, and is warmed up to after 40 DEG C and adds the Tadalafei bulk drug and sodium pyrosulfite of recipe quantity, continues to stir 1h to equal
Room temperature is down to after even, content is obtained；
(2) soft capsule is prepared：It is uniformly mixed in glycerine addition water the being placed in glue tank for taking recipe quantity, was subsequently adding 80 mesh
The titanium dioxide and yellow ferric oxide of sieve are well mixed, and are subsequently adding gelatin and are heated to 70 DEG C；Continue to stir 1h to gelatin
Stop stirring after being completely dissolved；Vacuum holding vacuum bag -0.09Mpa is opened after Gelatin makes glue degassing 30min, has deaerated
Lower the temperature 60 DEG C after finishing, it is standby after standing 24h；
(3) pill：Encapsulating machine is heated after being debugged to sprinkler body, and control temperature is at 35 DEG C；Adjustment revolving die pressure, with firm
Extrude capsule and pill well to be advisable, it is to avoid pressure crosses conference mold damage.Loading amount regulation is carried out, sampling detection extrudes the crack matter of capsule and pill
Amount, outward appearance, content weight, adjust, untill meeting the requirements in time；Roller is opened, the capsule and pill sizing that will be suppressed；Will pressure
The capsule and pill of system takes out after roller sizing, is placed in 30 DEG C, is dried in the environment of below RH50%, and the capsule severe edema due to hypofunction of the spleen of sampling detection at any time
Point, when the capsule severe edema due to hypofunction of the spleen point is 8%~12%, stop drying.
Claims (10)
1. a kind of Tadalafei soft capsule preparation, including soft capsule and content, it is characterised in that：The content prescription is：
Tadalafei raw material 0.1g ~ 0.5g；
Labraso 200g ~ 250g；
Unigly GO 102S 30g ~ 60g；
Median chain triglyceride oil 50g ~ 100g；
DBPC 2,6 ditertiary butyl p cresol 0.02g ~ 0.05g.
2. soft capsule preparation as claimed in claim 1, it is characterised in that：The content prescription is：
Tadalafei raw material 0.1g；
Labraso 220g ~ 240g；
Unigly GO 102S 40g ~ 50g；
Median chain triglyceride oil 60g ~ 90g；
DBPC 2,6 ditertiary butyl p cresol 0.03g ~ 0.04g.
3. soft capsule preparation as claimed in claim 1, it is characterised in that：The content prescription is：
Tadalafei raw material 0.2g；
Labraso 220g；
Unigly GO 102S 45g；
Median chain triglyceride oil 75g；
DBPC 2,6 ditertiary butyl p cresol 0.035g.
4. soft capsule preparation as claimed in claim 1, it is characterised in that：The content prescription is：
Tadalafei raw material 0.5g；
Labraso 235g；
Unigly GO 102S 48g；
Median chain triglyceride oil 78g；
DBPC 2,6 ditertiary butyl p cresol 0.04g.
5. soft capsule preparation as claimed in claim 1, it is characterised in that the prescription of the soft capsule is：
Gelatin 140mg ~ 180mg；
Glycerine 70mg ~ 100mg；
Yellow ferric oxide 0.1mg ~ 0.4mg；
Titanium dioxide 1mg ~ 3mg.
6. soft capsule preparation as claimed in claim 5, it is characterised in that the prescription of the soft capsule is：
Gelatin 160mg；
Glycerine 80mg；
Yellow ferric oxide 0.29mg；
Titanium dioxide 2mg.
7. soft capsule preparation as claimed in claim 5, it is characterised in that the prescription of the soft capsule is：
Gelatin 152mg；
Glycerine 92mg；
Yellow ferric oxide 0.35mg；
Titanium dioxide 2.5mg.
8. the technique for preparing any Tadalafei soft capsule preparation in claim 1 ~ 7, comprises the following steps：
（1）Prepare content：Take Labraso, Unigly GO 102S and the acid of medium chain triglyceride three of recipe quantity
Ester is stirred, and the Tadalafei bulk drug and BHT of recipe quantity are added after intensification, continues to stir
After be down to room temperature, obtain content；
（2）Prepare soft capsule：It is uniformly mixed in glycerine addition water the being placed in glue tank for taking recipe quantity, is subsequently adding sieving
Titanium dioxide and yellow ferric oxide are well mixed, are subsequently adding gelatin and are heated to 60 DEG C ~ 80 DEG C；Continue to stir complete to gelatin
CL；Vacuum is opened after Gelatin makes glue deaerate, and degassing is lowered the temperature after finishing；
（3）Pill：Inside Contents Fill to soft capsule, will shape, dry using soft capsule, obtain pastille soft capsule.
9. preparation technology as claimed in claim 8, it is characterised in that：The Labraso, polyglycereol
Oleate and median chain triglyceride oil are stirred, and Tadalafei bulk drug and 2,6- di-t-butyl pair are added after being warming up to 40 DEG C
Cresols.
10. preparation technology as claimed in claim 8, it is characterised in that：The capsule severe edema due to hypofunction of the spleen of the pastille soft capsule is divided into 8% ~ 12%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710079754.4A CN106822028A (en) | 2017-02-15 | 2017-02-15 | A kind of Tadalafei soft capsule preparation and its preparation technology |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710079754.4A CN106822028A (en) | 2017-02-15 | 2017-02-15 | A kind of Tadalafei soft capsule preparation and its preparation technology |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106822028A true CN106822028A (en) | 2017-06-13 |
Family
ID=59129036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710079754.4A Pending CN106822028A (en) | 2017-02-15 | 2017-02-15 | A kind of Tadalafei soft capsule preparation and its preparation technology |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106822028A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103271885A (en) * | 2013-05-23 | 2013-09-04 | 浙江华海药业股份有限公司 | Tadalafil orally disintegrating tablet and preparation method thereof |
| CN105395517A (en) * | 2015-12-11 | 2016-03-16 | 成都华宇制药有限公司 | Dutasteride soft capsule preparation and preparation process thereof |
-
2017
- 2017-02-15 CN CN201710079754.4A patent/CN106822028A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103271885A (en) * | 2013-05-23 | 2013-09-04 | 浙江华海药业股份有限公司 | Tadalafil orally disintegrating tablet and preparation method thereof |
| CN105395517A (en) * | 2015-12-11 | 2016-03-16 | 成都华宇制药有限公司 | Dutasteride soft capsule preparation and preparation process thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105395517B (en) | A kind of dutasteride's soft capsule preparation and its preparation technology | |
| EP1007009B1 (en) | A pharmaceutical composition having two coating layers | |
| JP4979181B2 (en) | Glycation inhibitors and uses thereof | |
| CN101983064B (en) | Absorbent ingestible agents and associated methods of manufacture and use | |
| JPH09509184A (en) | Controlled release composition | |
| JP5066448B2 (en) | Compositions and methods for the prevention or treatment of stomatitis | |
| CN106822028A (en) | A kind of Tadalafei soft capsule preparation and its preparation technology | |
| JP2015528474A (en) | Application of 3-n-butylisoindolinone in the preparation of drugs for the prevention and treatment of cerebral infarction | |
| KR101320945B1 (en) | Composition comprising s-allyl-l-cysteine for preventing or treating colitis and medicinal products | |
| KR102191621B1 (en) | Granule composition with improved off flavor and method for producing the same | |
| CN106727353A (en) | A kind of Tadalafei solid dispersion preparation and preparation method thereof | |
| CN107898768A (en) | A kind of tolvaptan soft capsule preparation and its preparation process | |
| CN106667953A (en) | Apremilast soft capsule preparation and preparation process thereof | |
| CN106580913A (en) | Trelagliptin succinate soft capsule preparation and preparation process thereof | |
| CN107898770A (en) | A kind of Zaltoprofen soft capsule preparation and its preparation process | |
| CN1883515A (en) | Bee pollen soft capsule and preparation method thereof | |
| JP2003113100A (en) | Calorigenic protein-expressing promoter and composition containing the same | |
| CN106667954A (en) | Diacerein soft capsule preparation and preparation process thereof | |
| CN110446505A (en) | For treating dermopathic conjoint therapy | |
| CN107998100A (en) | A kind of Febustat soft capsule preparation and its preparation process | |
| CN107898769A (en) | A kind of nebivolol hydrochloric acid soft capsule preparation and its preparation process | |
| CN106667955A (en) | Minodronic acid soft capsule preparation and preparation technology thereof | |
| CN107982267A (en) | A kind of razaxaban soft capsule preparation and its preparation process | |
| CN107898771A (en) | A kind of ranolazine soft capsule preparation and its preparation process | |
| CN106667956A (en) | Febuxostat soft capsule preparation and preparation technology thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170613 |
|
| WD01 | Invention patent application deemed withdrawn after publication |